Sambika Tablets 5/20 mg
Amlodipine Besylate 6.944mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
MFDS item code 201902834 · Approved 2019.05.02
This product's status changed to Expired on 2024.05.02. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of essential hypertension not controlled with monotherapy
This medication is used for the treatment of patients with essential hypertension whose blood pressure is not well controlled with either amlodipine or olmesartan medoxomil monotherapy. This drug dilates blood vessels, lowering blood pressure and reducing the cardiovascular burden. It helps prevent complications due to hypertension, thereby improving the patient's health status.
Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended that it be taken at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal insufficiency (creatine clearance 20-60mL/min) is 20 mg once daily, and use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal insufficiency. ∘Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while closely monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be monitored closely. This medicine should not be administered to patients with severe hepatic impairment. (See section 2, Patients who should not receive this medicine, under Precautions for Use.) ∘Elderly patients: Generally, start treatment at a low dose. When adjusting the dose, take the patient's renal or cardiac function and comorbidities into consideration. In elderly patients, blood pressure should be monitored closely and more frequently.
∘Pediatrics: The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.
This drug can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it must be discontinued immediately if pregnancy is confirmed. Patients with allergies to any of the ingredients in this medication, those who are pregnant or nursing, and those with certain conditions such as severe liver disease, aortic stenosis, biliary obstruction, or who are undergoing dialysis should not take this medication. Patients who are depleted of fluid or salt, those with severe obstructive coronary artery disease, congestive heart failure, or impaired renal function must take this medication with caution and monitor for symptoms such as hypotension or worsening renal function. Side effects such as dizziness, headache, hypotension, cough, dyspepsia, skin rash, myalgia, edema may occur while taking this medication, and if any adverse symptoms appear, consultation with a healthcare professional is advised. This medication may pose risks to the fetus during pregnancy; hence those planning or currently pregnant should inform their healthcare provider and may need to switch to a safer alternative if necessary. In breastfeeding mothers, this medication may be transferred to breast milk and affect infants; therefore, it is recommended to either stop breastfeeding or discontinue the medication. The safety and efficacy of this medication have not been established in pediatric patients under 18 years of age, and its use is not recommended for them. Elderly patients may have decreased renal and liver function, so dosage adjustment and monitoring are necessary while taking this medication. In case of overdose, symptoms like hypotension and tachycardia may occur, and immediate medical assistance is required while monitoring cardiac and respiratory functions regularly. This medication should be stored in a place away from direct sunlight and moisture, out of reach of children, and transferring to another container should be avoided. During the use of this medication, there may be interactions with other drugs, so if other medications are being taken, it is essential to inform the healthcare provider.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. The storage temperature should be maintained between 1°C and 30°C room temperature. Proper storage like this can help maintain the effectiveness and safety of the medication for a longer time.
White, round film-coated tablets
30 tablets (10 tablets/PTP x 3)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Amlodipine Besylate 6.944mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.